Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (41-50 of 436) with videos related to

Pageof 44
Sort By:
Health Affairs (Project Hope)|October 6, 2010
'Bench to behavior': translating comparative effectiveness research into improved clinical practiceJerry Avorn, Michael Fischer
BMJ (Clinical Research Ed.)|February 10, 2011
Postmarketing studies of drug safetySebastian Schneeweiss, Jerry Avorn
Journal of Clinical Epidemiology|May 3, 2005
A review of uses of health care utilization databases for epidemiologic research on therapeuticsSebastian Schneeweiss, Jerry Avorn
Annals of Internal Medicine|April 20, 2011
A hemorrhage of off-label useJerry Avorn, Aaron Kesselheim
The New England Journal of Medicine|July 29, 2009
Managing drug-risk information--what to do with all those new numbersJerry Avorn, Sebastian Schneeweiss
The New England Journal of Medicine|January 16, 2009
Antipsychotic agents and sudden cardiac death--how should we manage the risk?Sebastian Schneeweiss, Jerry Avorn
JAMA|September 2, 2020
Regulatory Decision-making on COVID-19 Vaccines During a Public Health EmergencyJerry Avorn, Aaron Kesselheim
BMJ (Clinical Research Ed.)|July 7, 2009
Imuunosuppressants, mortality, and risk of cancerJerry Avorn, Sebastian Schneeweiss
The New England Journal of Medicine|June 9, 2006
Highlights and a hidden hazard--the FDA's new labeling regulationsJerry Avorn, William Shrank
BMJ (Clinical Research Ed.)|April 10, 2008
Adverse Drug Reactions in Elderly People: A substantial cause of preventable illnessJerry Avorn, William H Shrank
Pageof 44

Showing results (41-50 of 436) with videos related to

Sort By:
Pageof 44
Health Affairs (Project Hope)|October 6, 2010
'Bench to behavior': translating comparative effectiveness research into improved clinical practiceJerry Avorn, Michael Fischer
BMJ (Clinical Research Ed.)|February 10, 2011
Postmarketing studies of drug safetySebastian Schneeweiss, Jerry Avorn
Journal of Clinical Epidemiology|May 3, 2005
A review of uses of health care utilization databases for epidemiologic research on therapeuticsSebastian Schneeweiss, Jerry Avorn
Annals of Internal Medicine|April 20, 2011
A hemorrhage of off-label useJerry Avorn, Aaron Kesselheim
The New England Journal of Medicine|July 29, 2009
Managing drug-risk information--what to do with all those new numbersJerry Avorn, Sebastian Schneeweiss
The New England Journal of Medicine|January 16, 2009
Antipsychotic agents and sudden cardiac death--how should we manage the risk?Sebastian Schneeweiss, Jerry Avorn
JAMA|September 2, 2020
Regulatory Decision-making on COVID-19 Vaccines During a Public Health EmergencyJerry Avorn, Aaron Kesselheim
BMJ (Clinical Research Ed.)|July 7, 2009
Imuunosuppressants, mortality, and risk of cancerJerry Avorn, Sebastian Schneeweiss
The New England Journal of Medicine|June 9, 2006
Highlights and a hidden hazard--the FDA's new labeling regulationsJerry Avorn, William Shrank
BMJ (Clinical Research Ed.)|April 10, 2008
Adverse Drug Reactions in Elderly People: A substantial cause of preventable illnessJerry Avorn, William H Shrank
Pageof 44